Literature DB >> 10920251

Structural analysis of N-linked sugar chains of human blood clotting factor IX.

Y Makino1, K Omichi, N Kuraya, H Ogawa, H Nishimura, S Iwanaga, S Hase.   

Abstract

The structures of pan class="Chemical">N-glycans of n>n class="Species">human blood clotting factor IX were studied. N-Glycans liberated by hydrazinolysis were N-acetylated and the reducing-end sugar residues were tagged with 2-aminopyridine. The pyridylamino (PA-) sugar chains thus obtained were purified by HPLC. Each PA-sugar chain was analyzed by two-dimensional sugar mapping combined with glycosidase digestion. The major structures of the N-linked sugar chains of human factor IX were found to be sialotetraantennary and sialotriantennary chains with or without fucose residues. These highly sialylated sugar chains are located on the activation peptide of the protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10920251     DOI: 10.1093/oxfordjournals.jbchem.a022738

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  12 in total

1.  Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

Authors:  Henrik Østergaard; Jais R Bjelke; Lene Hansen; Lars Christian Petersen; Anette A Pedersen; Torben Elm; Flemming Møller; Mette B Hermit; Pernille K Holm; Thomas N Krogh; Jørn M Petersen; Mirella Ezban; Brit B Sørensen; Mette D Andersen; Henrik Agersø; Haleh Ahmadian; Kristoffer W Balling; Marie Louise S Christiansen; Karin Knobe; Timothy C Nichols; Søren E Bjørn; Mikael Tranholm
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

2.  Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes.

Authors:  Theresa Lindhout; Umar Iqbal; Lisa M Willis; Anne N Reid; Jianjun Li; Xin Liu; Maria Moreno; Warren W Wakarchuk
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

3.  Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk.

Authors:  Geun-Cheol Gil; William H Velander; Kevin E Van Cott
Journal:  Glycobiology       Date:  2008-05-02       Impact factor: 4.313

Review 4.  Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide.

Authors:  K E Van Cott; P E Monahan; T C Nichols; W H Velander
Journal:  Haemophilia       Date:  2004-10       Impact factor: 4.287

5.  N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C.

Authors:  Geun-Cheol Gil; William H Velander; Kevin E Van Cott
Journal:  Proteomics       Date:  2009-05       Impact factor: 3.984

6.  Coagulation Factor IX for Hemophilia B Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov
Journal:  Acta Naturae       Date:  2012-04       Impact factor: 1.845

7.  Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.

Authors:  Takehisa Kitazawa; Keiko Esaki; Tatsuhiko Tachibana; Shinya Ishii; Tetsuhiro Soeda; Atsushi Muto; Yoshiki Kawabe; Tomoyuki Igawa; Hiroyuki Tsunoda; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Thromb Haemost       Date:  2017-04-28       Impact factor: 5.249

8.  Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling.

Authors:  Zhigang Wu; Peng Zhou; Xiaoxin Li; Hui Wang; Delun Luo; Huaiyao Qiao; Xiao Ke; Jian Huang
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

9.  Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.

Authors:  Dougald M Monroe; Richard J Jenny; Kevin E Van Cott; Shelly Buhay; Laura L Saward
Journal:  Adv Hematol       Date:  2016-02-21

10.  A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX.

Authors:  S V Kovnir; N A Orlova; M I Shakhparonov; K G Skryabin; A G Gabibov; I I Vorobiev
Journal:  Acta Naturae       Date:  2018 Jan-Mar       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.